StreetInsider.com News Articles

Form 8-K PULSE BIOSCIENCES, INC. For: Jun 10

Wed, 10 Jun 2026 08:55:00 -0400

si-local-file:///var/storage/secattach/20260610/26627430.html

Form 8-K PULSE BIOSCIENCES, INC. For: Jun 10

Wed, 10 Jun 2026 08:55:00 -0400

si-local-file:///var/storage/secattach/20260610/26627430.html

Pulse Biosciences plans warrant redemption after stock price trigger

Wed, 10 Jun 2026 07:01:07 -0400

Pulse Biosciences Inc. (NASDAQ: PLSE) announced it will redeem remaining warrants from its 2024 rights offering after meeting required stock price conditions. The company plans to deliver a redemption notice around June 10, 2026, for warrants that can be exercised until July 13, 2026, at $11.00 per share.

The redemption became possible after the company's volume weighted average price exceeded $22.00 per share for twenty consecutive trading days, with an average of $25.17 during that period. Warrants not exercised by the July deadline will be redeemed for $0.01 per warrant.

The bioelectric medicine company received $60 million from its July 2024 rights

Pulse Biosciences plans warrant redemption after stock price trigger

Wed, 10 Jun 2026 07:01:07 -0400

The bioelectric medicine company received $60 million from its July 2024 rights

Pulse Biosciences, Inc. Announces Planned Redemption of Warrants

Wed, 10 Jun 2026 07:00:00 -0400

HAYWARD, Calif.--(BUSINESS WIRE)-- Pulse Biosciences, Inc. (Nasdaq: PLSE), a company leveraging its novel and proprietary Nanosecond Pulsed Field Ablation™ (nano-PFA or nsPFA™) technology, today announced that it intends to deliver an irrevocable notice of redemption, on or about June 10, 2026, to redeem the remaining common stock warrants issued by the Company as part of its July 3, 2024 rights offering. These outstanding common stock warrants (the “200% Warrants”), which were issued in the Company’s 2024 rights offering (the “Rights Offering”), pursuant to the Company’s Registration Statement on Form S-3, as amended (File No. 333-278494), may be

Pulse Biosciences, Inc. Announces Planned Redemption of Warrants

Wed, 10 Jun 2026 07:00:00 -0400

Pulse Biosciences, Inc. Announces Planned Redemption of Warrants

Wed, 10 Jun 2026 07:00:00 -0400

Pulse Biosciences, Inc. Announces Planned Redemption of Warrants

Wed, 10 Jun 2026 07:00:00 -0400

Canaccord Starts Pulse Biosciences (PLSE) at Buy

Thu, 04 Jun 2026 06:09:41 -0400

Canaccord analyst William Plovanic initiates coverage on Pulse Biosciences (NASDAQ: PLSE) with a Buy rating and a price target of $32.00.

The analyst comments "Bottom line: We are initiating coverage on Pulse BioSciences with a BUY rating and a $32 price target. We believe Pulse has a technically-and-clinically differentiated cardiac ablation platform to meet the evolving needs of electrophysiologists (EP) with a novel mechanism of action, nanosecond pulsed field ablation (nsPFA). Pulse’s nsPFA technology builds on the first-generation microsecond pulsed field ablation technology owned by the large, strategic Med-Tech companies (ABT, BSX, JNJ, MDT), and Pulse’s evolution of PFA has shown

Canaccord Starts Pulse Biosciences (PLSE) at Buy

Thu, 04 Jun 2026 06:09:41 -0400

Canaccord analyst William Plovanic initiates coverage on Pulse Biosciences (NASDAQ: PLSE) with a Buy rating and a price target of $32.00.

Pulse Biosciences to Present at the Goldman Sachs 47th Annual Global Healthcare Conference 2026

Wed, 27 May 2026 16:05:00 -0400

Pulse Biosciences’ Management is scheduled to present on Wednesday, June 10, at 10:00 am ET. A live and recorded webcast of the fireside chat will be available on the “Events Calendar and Presentations” page of the company’s investor website at http://investors.pulsebiosciences.com/.

About Pulse Biosciences®

Pulse Biosciences is a novel bioelectric medicine company committed to health innovation that

Pulse Biosciences to Present at the Goldman Sachs 47th Annual Global Healthcare Conference 2026

Wed, 27 May 2026 16:05:00 -0400

About Pulse Biosciences®

Pulse Biosciences is a novel bioelectric medicine company committed to health innovation that

Pulse Biosciences to Present at the Goldman Sachs 47th Annual Global Healthcare Conference 2026

Wed, 27 May 2026 16:05:00 -0400

About Pulse Biosciences®

Pulse Biosciences is a novel bioelectric medicine company committed to health innovation that

Pulse Biosciences to Present at the Goldman Sachs 47th Annual Global Healthcare Conference 2026

Wed, 27 May 2026 16:05:00 -0400

About Pulse Biosciences®

Pulse Biosciences is a novel bioelectric medicine company committed to health innovation that

Form 4/A PULSE BIOSCIENCES, INC. For: May 11 Filed by: DUGGAN ROBERT W

Fri, 15 May 2026 19:26:00 -0400

si-local-file:///var/storage/secattach/20260515/26508362.html

Form 4/A PULSE BIOSCIENCES, INC. For: May 11 Filed by: DUGGAN ROBERT W

Fri, 15 May 2026 19:26:00 -0400

si-local-file:///var/storage/secattach/20260515/26508362.html

Form 10-Q PULSE BIOSCIENCES, INC. For: Mar 31

Thu, 14 May 2026 09:03:00 -0400

si-local-file:///var/storage/secattach/20260514/26491208.html

Form 10-Q PULSE BIOSCIENCES, INC. For: Mar 31

Thu, 14 May 2026 09:03:00 -0400

si-local-file:///var/storage/secattach/20260514/26491208.html

Form SCHEDULE 13D/A PULSE BIOSCIENCES, INC. Filed by: DUGGAN ROBERT W

Wed, 13 May 2026 18:37:00 -0400

si-local-file:///var/storage/secattach/20260513/26487886.html

Form SCHEDULE 13D/A PULSE BIOSCIENCES, INC. Filed by: DUGGAN ROBERT W

Wed, 13 May 2026 18:37:00 -0400

si-local-file:///var/storage/secattach/20260513/26487886.html

Pulse Biosciences co-chairmen buy $13.3 million in company stock

Tue, 12 May 2026 07:01:12 -0400

Pulse Biosciences Inc. (NASDAQ: PLSE) announced that its co-chairmen purchased approximately $13.3 million worth of company stock through its at-the-market equity offering program.

Robert Duggan and Chief Executive Officer Paul LaViolette acquired 675,233 shares of common stock during the company's designated trading window, according to a press release statement.

Pulse Biosciences develops nPulse technology using nanosecond pulsed field ablation energy for medical applications. The company is pursuing development of its technology for treating atrial fibrillation and other medical markets.

The purchases were completed through the company's ATM program, which allows for the sale of shares directly into the market at prevailing prices.

Pulse Biosciences co-chairmen buy $13.3 million in company stock

Tue, 12 May 2026 07:01:12 -0400

Pulse Biosciences Inc. (NASDAQ: PLSE) announced that its co-chairmen purchased approximately $13.3 million worth of company stock through its at-the-market equity offering program.

Robert Duggan and Chief Executive Officer Paul LaViolette acquired 675,233 shares of common stock during the company's designated trading window, according to a press release statement.

The purchases were completed through the company's ATM program, which allows for the sale of shares directly into the market at prevailing prices.

Pulse Biosciences co-chairmen buy $13.3 million in company stock

Tue, 12 May 2026 07:01:12 -0400

Pulse Biosciences Inc. (NASDAQ: PLSE) announced that its co-chairmen purchased approximately $13.3 million worth of company stock through its at-the-market equity offering program.

Robert Duggan and Chief Executive Officer Paul LaViolette acquired 675,233 shares of common stock during the company's designated trading window, according to a press release statement.

The purchases were completed through the company's ATM program, which allows for the sale of shares directly into the market at prevailing prices.

ATM Equity Purchases by Pulse Biosciences’ Co-Chairmen Total Approximately $13.3 Million

Tue, 12 May 2026 07:00:00 -0400

HAYWARD, Calif.--(BUSINESS WIRE)-- Pulse Biosciences, Inc. (Nasdaq: PLSE), developer of nPulse™ technology using proprietary nanosecond pulsed field ablation (nsPFA™) energy, today announced its Co-Chairmen of the Board, Robert Duggan and Chief Executive Officer Paul LaViolette, completed purchases of Pulse Biosciences’ common stock through its at-the-market equity offering program (ATM) during the Company’s designated trading window.

In total, the Co-Chairmen acquired 675,233 shares of Pulse Biosciences’ common stock for an aggregate purchase price of approximately $13.3 million.

About Pulse Biosciences®

Pulse Biosciences is a novel bioelectric medicine company committed to health innovation that has the intention as well as potential to

ATM Equity Purchases by Pulse Biosciences’ Co-Chairmen Total Approximately $13.3 Million

Tue, 12 May 2026 07:00:00 -0400

In total, the Co-Chairmen acquired 675,233 shares of Pulse Biosciences’ common stock for an aggregate purchase price of approximately $13.3 million.

About Pulse Biosciences®

Pulse Biosciences is a novel bioelectric medicine company committed to health innovation that has the intention as well as potential to